Swipe the table sideways for more columns.

TrialConditionsStatusPhaseUpdatedMore infoNCT ID
Efficacy and Safety of MSC-NTF (NurOwn) in Participants With Early Symptomatic ALS and Moderate Disease Presentation in ALS (ENDURANCE STUDY)Nutritional and Metabolic Diseases, TDP-43 proteinopathy, amyotrophic lateral sclerosis, central nervous system disorder, metabolic disease, motor neuron disorder, nervous system disorder, neurodegenerative disease, neuromuscular disease, proteostasis deficiencies, spinal cord disorderNot yet recruitingPhase 32025-05-22NCT06973629

1 results · Page 1 of 1

Swipe the table sideways for more columns.

OrganizationsLinked trials
Brainstorm-Cell Therapeutics1

15 results · Page 1 of 1

Swipe the table sideways for more columns.

Research sitesCityCountryLinked trials
Barrow Neurological InstitutePhoenixUnited States50
California Pacific Medical CenterSan FranciscoUnited States12
Mayo ClinicRochesterUnited States664
Mayo ClinicJacksonvilleUnited States122
Northwestern MedicineChicagoUnited States36
Nova Southeastern UniversityDavieUnited States1
Providence ALS CenterPortlandUnited States3
Sean M. Healey & AMG Center for ALS at Massachusetts General HospitalBostonUnited States2
Temple University of The Commonwealth System of Higher EducationPhiladelphiaUnited States4
University of California San Diego Medical CenterLa JollaUnited States4
University of California, San FranciscoSan FranciscoUnited States294
University of Colorado Anschutz Medical Campus School of MedicineAuroraUnited States1
University of Massachusetts Medical SchoolWorcesterUnited States17
University of South FloridaTampaUnited States73
University of Southern CaliforniaLos AngelesUnited States110